CTLA4 and melanoma: Mechanisms by which tumor-intrinsic active β-catenin signaling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy were discovered in an orthotopic mouse model of melanoma.